University of Helsinki
Distinct nicotinic acetylcholine receptors in dorsal and ventral striatum: Basis for novel therapies of Parkinson's disease
Academy of Finland
Parkinson´s disease is levodopa. However, levodopa treatment is plagued by adverse effects, especially dyskinesias that affect the whole body. Presently, there is no effective drug therapy against dyskinesias. In animal models, it has been shown that nicotinic drugs could be effective in treating dyskinesias. This study aims at clarifying what are the mechanisms of levodopa-induced dyskinesias and, further, how nicotine elicits its antidyskinetic effect. The aim of the proposed research is to build the basis for development of improved drug therapy for currently poorly treated aspects of Parkinson´s disease.